A Study of LY4515100 in Participants With Pain Following Third Molar Removal
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-40
SponsorEli Lilly and Company
About this trial
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Eligibility criteria
Qualifiers
Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²) inclusive.
Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.
Disqualifiers
Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.
Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.
Positive urine drug screen or alcohol test during screening or on the day of surgery.
Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.
Trial design
Treatments tested in this trial
- LY4515100
- Placebo
Treatment groups
212 Participants
are divided into 2 treatment groupsLocations
1JBR Clinical Research84107, Salt Lake CityUtah, United States
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov